Clinical trials have shown that Femprox® exerts a relaxant effect on vulvar and clitoral blood vessels in women, leading to increased blood flow. This leads to pelvic engorgement and enhanced secretion activity of the vulvar epithelium. The resultant increase in lubrication and sensory feedback due to pelvic engorgement is believed to produce a clinically significant increase in sexual arousal in women with FSAD. Apricus Bio's Femprox® enables a rapid permeation of blood deep into the target tissues, thus potentially enabling a new pharmacotherapy for the treatment of FSAD.Dr. Damaj stated, "We are pleased that Drs. Goldstein, Kaminetsky and Nehra have agreed to serve on our new Sexual Dysfunction Clinical Advisory Board. Their expertise will be key to helping us move forward with our Femprox® program as well as in the development of other products in the male and female sexual dysfunction field."
Apricus Biosciences Announces Formation Of Clinical Advisory Board As Part Of Its Plans To Further The Clinical Development Of Femprox(R)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.